Accelovance nominated as Best CRO for 2018 Vaccine Industry Excellence (ViE) Awards for 11th straight year
ROCKVILLE, MD, March 5, 2018 –
Accelovance, a therapeutically focused contract research organization (CRO), has again been named a finalist for “Best Contract Research Organization” at the upcoming Vaccine Industry Excellence (ViE) Awards hosted by the World Vaccine Congress.
This is the 11th consecutive year Accelovance has been honored as a finalist for the award, making Accelovance the only CRO who has been nominated every year since the inception of the ViE Awards. Of those nominations, Accelovance has won the award three times and received a “Highly Recommended” distinction twice.
“We are honored to be named a finalist for the ‘Best CRO’ Award for an unprecendeted 11th time at the World Vaccine Congress. Our unbroken streak of consecutive years receiving this nomination speaks volumes to the skill and knowledge of our employees, the strong relationships we have developed with our clients, and the impact we have made with Sponsors in the field of vaccine development” said Stephen J. Trevisan, Accelovance Chief Executive Officer. Mr Trevisan went on to add “I believe the nomination is a reflection of Accelovance’s transition into therapeutic vaccine development in the immuno-oncology space. We have taken the best practices from prophylactic vaccine delevelopment and translated them into the therapeutic space. Activities such as patient pooling and pre-screening in the oncology space definitely can accelerate enrollment and shorten development timelines.”
Accelovance and the other shortlisted finalists will be evaluated by a Scientific Advisory Board for quality of services, performance, client satisfaction, Sponsor relationships, and the overall value brought to study Sponsors. Accelovance is well regarded within the clinical research industry for its experience in managing vaccine trials, including successful clinical oversight, innovative patient enrollment and retention strategies, and for providing full service solutions to clients. Award winners will be announced at the 2018 Annual World Vaccine Congress in Washington, D.C. April 3 - 5, 2018.
Accelovance is an award winning, clinical development Contract Research Organization (CRO) focused on both prophylactic and therapeutic vaccines, oncology, dermatology, pain, nutrition and women’s health (Phase I-IV programs). Providing global full CRO services to pharmaceutical companies, biotechs, CROs, and academic institutions, Accelovance supports client needs by leveraging operational knowledge and patient recruitment strategies that result in successful clinical trials. Established in 2005 with a corporate mission to improve the quality and predictability in clinical research, Accelovance has made significant strides in the industry by combining strong business and operational perspective with clinical and medical expertise.
Alison Cundari, Marketing Manager